Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry

Top-down mass spectrometry holds tremendous potential for the characterization and quantification of intact proteins, including individual protein isoforms and specific posttranslationally modified forms. This technique does not require antibody reagents and thus offers a rapid path for assay development with increased specificity based on the amino acid sequence. Top-down MS is efficient whereby intact protein mass measurement, purification by mass separation, dissociation, and measurement of product ions with ppm mass accuracy occurs on the seconds to minutes time scale. Moreover, as the analysis is based on the accurate measurement of an intact protein, top-down mass spectrometry opens a research paradigm to perform quantitative analysis of “unknown” proteins that differ in accurate mass. As a proof of concept, we have applied differential mass spectrometry (dMS) to the top-down analysis of apolipoproteins isolated from human HDL3. The protein species at 9415.45 Da demonstrates an average fold change of 4.7 (p-value 0.017) and was identified as an O-glycosylated form of apolipoprotein C-III [NANA-(2 → 3)-Gal-β(1 → 3)-GalNAc, +656.2037 Da], a protein associated with coronary artery disease. This work demonstrates the utility of top-down dMS for quantitative analysis of intact protein mixtures and holds potential for facilitating a better understanding of HDL biology and complex biological systems at the protein level.

[1]  W. Blackstock,et al.  Proteomics: quantitative and physical mapping of cellular proteins. , 1999, Trends in biotechnology.

[2]  N. Kelleher,et al.  Decoding protein modifications using top-down mass spectrometry , 2007, Nature Methods.

[3]  J. Heinecke The HDL proteome: a marker–and perhaps mediator–of coronary artery disease Published, JLR Papers in Press, December 5, 2008. , 2009, Journal of Lipid Research.

[4]  Shu Zheng,et al.  Discovery and identification of potential biomarkers of papillary thyroid carcinoma , 2009, Molecular Cancer.

[5]  G. McAlister,et al.  A proteomics grade electron transfer dissociation-enabled hybrid linear ion trap-orbitrap mass spectrometer. , 2008, Journal of proteome research.

[6]  Lewis Y. Geer,et al.  Analysis of intact proteins on a chromatographic time scale by electron transfer dissociation tandem mass spectrometry. , 2007, International journal of mass spectrometry.

[7]  Yong-Bin Kim,et al.  ProSight PTM: an integrated environment for protein identification and characterization by top-down mass spectrometry , 2004, Nucleic Acids Res..

[8]  F W McLafferty,et al.  Biomolecule Mass Spectrometry , 1999, Science.

[9]  A. Tall,et al.  Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. , 2007, The Journal of clinical investigation.

[10]  John R. Yates,et al.  The biological impact of mass-spectrometry-based proteomics , 2007, Nature.

[11]  Matthew C Wiener,et al.  Quantitative analysis of complex peptide mixtures using FTMS and differential mass spectrometry , 2007, Journal of the American Society for Mass Spectrometry.

[12]  R. Hendrickson,et al.  Quantitative analysis of histone deacetylase-1 selective histone modifications by differential mass spectrometry. , 2008, Journal of proteome research.

[13]  R. Hegele,et al.  Is raising HDL a futile strategy for atheroprotection? , 2008, Nature Reviews Drug Discovery.

[14]  D. Hochstrasser,et al.  From Proteins to Proteomes: Large Scale Protein Identification by Two-Dimensional Electrophoresis and Arnino Acid Analysis , 1996, Bio/Technology.

[15]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[16]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[17]  J. Yates,et al.  A model for random sampling and estimation of relative protein abundance in shotgun proteomics. , 2004, Analytical chemistry.

[18]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[19]  D. Thelle,et al.  THE TROMSØHEART-STUDY HIGH-DENSITY LIPOPROTEIN AND CORONARY HEART-DISEASE: A PROSPECTIVE CASE-CONTROL STUDY , 1977, The Lancet.

[20]  Subramaniam Pennathur,et al.  Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. , 2007, The Journal of clinical investigation.

[21]  H. Eder,et al.  Protein-lipid relationships in human plasma. I. In normal individuals. , 1951, The American journal of medicine.

[22]  T. Ogura,et al.  Molecular cloning of a human apoC-III variant: Thr 74----Ala 74 mutation prevents O-glycosylation. , 1987, Journal of lipid research.

[23]  A. Scanu Studies on the conformation of human serum high-density lipoproteins HDL2 and HDL3. , 1965, Proceedings of the National Academy of Sciences of the United States of America.

[24]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[25]  G. Assmann,et al.  Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders. , 2003, Atherosclerosis.

[26]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[27]  A. Olsson Is high HDL cholesterol always good? , 2009, Annals of medicine.

[28]  A. Scanu,et al.  HDL: bridging past and present with a look at the future , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  H. Eder,et al.  Protein-lipid relationships in human plasma. II. In atherosclerosis and related conditions. , 1951, The American journal of medicine.

[30]  G. McAlister,et al.  Implementation of electron-transfer dissociation on a hybrid linear ion trap-orbitrap mass spectrometer. , 2007, Analytical chemistry.

[31]  J. O’Connell,et al.  A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection , 2008, Science.

[32]  A. Tall,et al.  ATP‐binding cassette transporters G1 and G4 mediate cholesterol and desmosterol efflux to HDL and regulate sterol accumulation in the brain , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. Mann,et al.  Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast , 2008, Nature.

[34]  R. Aebersold,et al.  Mass Spectrometry and Protein Analysis , 2006, Science.

[35]  Hongling Han,et al.  Electron transfer dissociation of iTRAQ labeled peptide ions. , 2008, Journal of proteome research.

[36]  E. Arnesen,et al.  The Tromsø Heart Study , 1983 .

[37]  T. Shaler,et al.  Quantification of proteins and metabolites by mass spectrometry without isotopic labeling or spiked standards. , 2003, Analytical chemistry.

[38]  F. McLafferty,et al.  Electron capture dissociation for structural characterization of multiply charged protein cations. , 2000, Analytical chemistry.

[39]  J. Shabanowitz,et al.  Peptide and protein sequence analysis by electron transfer dissociation mass spectrometry. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Mann,et al.  Analysis of proteins and proteomes by mass spectrometry. , 2001, Annual review of biochemistry.

[41]  R. Aebersold,et al.  Mass spectrometry-based proteomics , 2003, Nature.

[42]  C. Paweletz,et al.  Surface enhanced laser desorption ionization spectrometry reveals biomarkers for drug treatment but not dose , 2006, Proteomics.

[43]  F. McLafferty,et al.  Top down versus bottom up protein characterization by tandem high- resolution mass spectrometry , 1999 .

[44]  Guilong Cheng,et al.  Mass spectrometry of peptides and proteins. , 2005, Methods.

[45]  Farhad Rezaee,et al.  Proteomic analysis of high‐density lipoprotein , 2006, Proteomics.

[46]  Jingyuan Deng,et al.  Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. , 2010, Journal of proteome research.

[47]  Matthew C Wiener,et al.  Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. , 2010, Journal of proteome research.

[48]  B. Warrack,et al.  A tris (2-carboxyethyl) phosphine (TCEP) related cleavage on cysteine-containing proteins , 2010, Journal of the American Society for Mass Spectrometry.

[49]  F W McLafferty,et al.  Localization of labile posttranslational modifications by electron capture dissociation: the case of gamma-carboxyglutamic acid. , 1999, Analytical chemistry.

[50]  F. McLafferty,et al.  Electron Capture Dissociation of Multiply Charged Protein Cations. A Nonergodic Process , 1998 .

[51]  David L. Tabb,et al.  A proteomic view of the Plasmodium falciparum life cycle , 2002, Nature.

[52]  M. Mann,et al.  Properties of 13C-substituted arginine in stable isotope labeling by amino acids in cell culture (SILAC). , 2003, Journal of proteome research.

[53]  Lukas N. Mueller,et al.  An assessment of software solutions for the analysis of mass spectrometry based quantitative proteomics data. , 2008, Journal of proteome research.

[54]  G. Bernard,et al.  O-glycoside biomarker of apolipoprotein C3: responsiveness to obesity, bariatric surgery, and therapy with metformin, to chronic or severe liver disease and to mortality in severe sepsis and graft vs host disease. , 2009, Journal of proteome research.

[55]  Kyriakos E Kypreos ABCA1 promotes the de novo biogenesis of apolipoprotein CIII-containing HDL particles in vivo and modulates the severity of apolipoprotein CIII-induced hypertriglyceridemia. , 2008, Biochemistry.

[56]  J. Yates,et al.  Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.

[57]  B. Ueberheide,et al.  The utility of ETD mass spectrometry in proteomic analysis. , 2006, Biochimica et biophysica acta.

[58]  S. Gygi,et al.  Quantitative Cancer Proteomics: Stable Isotope Labeling with Amino Acids in Cell Culture (SILAC) as a Tool for Prostate Cancer Research*S , 2004, Molecular & Cellular Proteomics.

[59]  R. Hendrickson,et al.  Differential mass spectrometry of rat plasma reveals proteins that are responsive to 17beta-estradiol and a selective estrogen receptor modulator PPT. , 2008, Journal of proteome research.

[60]  Yong-Bin Kim,et al.  ProSight PTM 2.0: improved protein identification and characterization for top down mass spectrometry , 2007, Nucleic Acids Res..

[61]  S. Goldstein,et al.  A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. , 1981, Journal of lipid research.

[62]  M. Wiener,et al.  Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. , 2004, Analytical chemistry.